Anaplastic thyroid cancer is incredibly aggressive, causing over half of all thyroid cancer deaths despite being rare. This review asks if combining new immunotherapies with targeted drugs can finally turn the tide against this deadly disease. Anaplastic thyroid carcinoma is a rare but extremely aggressive form of thyroid cancer that currently lacks effective treatments.

Recent years have seen significant progress with targeted therapies acting on specific genetic mutations found in these tumor cells. The FDA approved dabrafenib combined with trametinib in 2018 for BRAF-positive cases, confirming the potential of targeting specific pathways.

Simultaneously, researchers are exploring immunotherapy and combinations with other treatments to enhance anti-tumor effects. Although thyroid cancer is common globally, anaplastic thyroid carcinoma accounts for only about two percent of cases. Despite its rarity, this subtype is responsible for more than fifty percent of all thyroid cancer-related deaths.

This figure illustrates the two primary signaling pathways driving Anaplastic Thyroid Cancer: the MAPK pathway and the PI3K/AKT/mTOR pathway. The diagram visualizes how extracellular growth factors bind to receptor tyrosine kinases on the cell surface, triggering a cascade of internal signals that promote tumor proliferation and angiogenesis.

Crucially, the authors map specific targeted therapies to these mechanisms, showing where drugs like Sorafenib or Trametinib intervene to block the activity of essential molecules such as Ras, Raf, and mTOR. Targeted therapy improves patient outcomes by blocking specific molecules essential for cancer growth while sparing normal cells.

High-throughput sequencing has identified common mutations like BRAF, RAS, and P53 that serve as targets for new drugs. Clinicians can now adjust treatment plans based on these findings to block pathways like RAS/RAF/ERK and PI3K/AKT/mTOR. Sorafenib was the first oral multi-kinase inhibitor tested, showing a thirty-five percent disease control rate in a trial of twenty patients.

However, a subsequent study in Japanese patients found sorafenib ineffective for anaplastic thyroid cancer, with zero symptom relief among ten patients. Lenvatinib showed promise in a phase II trial where four out of seventeen anaplastic thyroid cancer patients achieved remission.

Despite this encouraging response, a later exploratory trial was terminated because only one out of thirty-three patients had a partial response. BRAF mutations are found in forty-one percent of anaplastic thyroid cancer patients, making them a critical target for therapy.

A case study showed a patient treated with vemurafenib experienced almost complete elimination of metastatic disease after thirty-eight days. In a phase II study of seven patients, one achieved complete response and another achieved partial response to vemurafenib.

A phase II study of dabrafenib plus trametinib found that eleven out of fifteen patients with BRAF mutations entered remission. Due to this strong clinical activity, the FDA approved this combination for treating BRAF-positive anaplastic thyroid cancer. Table 1 outlines three ongoing clinical trials exploring targeted therapies for anaplastic thyroid cancer, highlighting the active research into overcoming treatment resistance.

The authors list specific agents like MLN0128 and Sorafenib, alongside a combination of Dabrafenib and Trametinib paired with radiation therapy. By detailing study phases ranging from Phase I to II and estimated enrollments between ten and forty-six patients, this table illustrates the current experimental landscape as researchers investigate appropriate timing and sequencing for these interventions.

Cancer immunotherapy works by inducing or enhancing specific immune responses to fight tumors through multiple mechanisms. Tumors often escape detection by the immune system through a process known as immune editing. Figure 2 illustrates the complex signaling network between a T cell, a cancer cell, and an antigen-presenting dendritic cell.

The diagram highlights how specific ligands bind to multiple receptors to deliver either co-stimulatory or inhibitory signals that regulate the immune response. For instance, it depicts the interaction where PD-1 on the T cell binds to PD-L1 on the cancer cell, alongside other checkpoint pathways like CTLA-4 and CD80/CD86.

This visual emphasizes the mechanism by which tumors can escape immune surveillance through these suppressive checkpoints. PD-L1 is highly expressed in anaplastic thyroid cancer tissues and is associated with poor patient prognosis. High expression of PD-1 and PD-L1 predicts worse overall survival and shorter progression-free survival for these patients.

A phase II trial of spartalizumab, a PD-1 inhibitor, achieved an overall remission rate of nineteen percent in patients with advanced disease. This result confirms that PD-1 inhibitors have good clinical activity and safety for patients with incurable malignant diseases.

While checkpoint inhibitors are generally better tolerated than chemotherapy, they can cause serious autoimmune side effects like colitis. Some patients show poor responses to these drugs, highlighting the need to overcome issues of toxicity and variable efficacy.

CD70 expression was found to be upregulated in nearly fifty percent of anaplastic thyroid cancer samples analyzed. This suggests that CD70 could serve as a valuable anti-tumor target for immunotherapy strategies. Blocking the CD47 receptor promotes macrophage phagocytosis and inhibits tumor growth in mouse models of anaplastic thyroid cancer.

These results suggest that targeting CD47 could potentially improve patient prognosis and supplement current treatment standards. CAR-T cells engineered to target ICAM-1 have shown strong anti-tumor activity leading to tumor eradication in mouse models. Clinical trials are now underway to test ICAM-1 CAR-T cells in patients with anaplastic thyroid cancer.

Table 2 catalogs four distinct clinical trials investigating immunotherapy for anaplastic thyroid cancer, primarily focusing on PD-1 antagonists. The authors list specific agents including HX008, pembrolizumab, and PDR001, noting that while some studies have completed by late 2020, others remain active or are not yet recruiting as of 2022.

This compilation highlights the ongoing research efforts to evaluate both single-agent efficacy and combination therapies involving CTLA-4 antagonists in this aggressive disease context. Combining pembrolizumab with lenvatinib effectively delayed disease progression with a median progression-free survival of sixteen point five months.

Researchers are currently studying whether adding cemiplimab to standard dabrafenib and trametinib treatment improves outcomes. Table 3 catalogs the clinical trials currently exploring combination strategies for anaplastic thyroid cancer, specifically pairing immunotherapy with chemotherapy or targeted agents.

The authors highlight that while these combined approaches show promise in experimental settings, the table reveals a landscape where many studies are still actively recruiting or have only recently completed phases like phase I and II. This visual evidence underscores the critical need for further research to validate whether combining PD-1 antagonists with drugs like lenvatinib offers superior outcomes compared to single-agent treatments.

While targeted therapies like BRAF inhibitors offer hope, the real breakthrough likely lies in combining them with immunotherapy to overcome resistance and improve survival for patients with this aggressive cancer.